Getting it right
This morning Dexcom (NASDAQ:DXCM) announced that their Follow app is now compatible with Android devices. According to a company issued press release;
“The app is a component of the Dexcom G4® PLATINUM Continuous Glucose Monitor System with Share™, the industry’s first mobile-connected CGM system. Already available to iOS-enabled devices, the Follow app allows family members, friends and caregivers (“Followers”) to remotely view a loved one’s glucose data and trends on their smart device, giving them peace of mind and reassurance when they are apart. CGM users (“Sharers”) can invite up to five Followers to view their glucose information via the Follow app. The Followers can view the Sharer’s glucose data and trends, as well as choose to receive alerts and notifications when the Sharer’s glucose levels are outside specified ranges.”
While this news was expected it shows once more why Dexcom should be considered the model when it comes to diabetes devices. The company correctly understands that as we move ever closer to interconnected diabetes management (IDM) plus outcomes based reimbursement diabetes devices must be platform agnostic that iPhone may be way cool and very popular but it is not the only platform used by patients.
Dexcom also understands that in the future the FDA will eventually allow readings to go directly to a smartphone therefore eliminating the need for a separate receiver. This is not just financially beneficial for the company but should also help expand the market for their technology which as we have stated before is the best in the business. Unlike other companies who constantly complain about the FDA, Dexcom is working with the agency.
To Diabetic Investor Dexcom is like a breath of fresh air as instead of bitching and moaning about this wacky world they are taking matters into their own hands. As we have stated many times regarding insulin pump companies the test isn’t building a device the test is running a device company. Talent in the diabetes device world is in short supply but something Dexcom has in abundance.
